Payment overview · 2025
General Payments
$202.08
8 reported records · 5 companies
Healthcare provider profile · identity verified
Sunil Prem, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · MONROE, LA · NPI 1417038746
Verified facts
What the public records show
CMS Open Payments records show Sunil Prem, M.D. received $202.08 in general payments during 2025 across 8 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 40.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Eliquis, Rexulti.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $82.57 | 40.9% | 4 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $56.52 | 28.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.44 | 15.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.66 | 8.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.89 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.08 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $82.57 | 4 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $56.52 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $31.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 294 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
294 | 34 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 61 |
| Eliquis | Apixaban | 294 | 34 |
| Potassium Chloride | Potassium Chloride | 290 | 57 |
| Gabapentin | Gabapentin | 289 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 51 |
| Memantine Hcl | Memantine Hcl | 222 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 32 |
| Metformin Hcl | Metformin Hcl | 189 | 35 |
| Lisinopril | Lisinopril | 170 | 34 |
| Losartan Potassium | Losartan Potassium | 169 | 28 |
| Donepezil Hcl | Donepezil Hcl | 167 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 33 |
| Furosemide | Furosemide | 150 | 36 |
| Meloxicam | Meloxicam | 150 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 25 |
| Famotidine | Famotidine | 115 | 19 |
| Levetiracetam | Levetiracetam | 115 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 21 |
| Omeprazole | Omeprazole | 90 | 14 |
| Sertraline Hcl | Sertraline Hcl | 88 | 17 |
| Trazodone Hcl | Trazodone Hcl | 87 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 23 |
| Xarelto | Rivaroxaban | 84 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 83 | suppressed |
| Lamotrigine | Lamotrigine | 72 | 16 |
| Januvia | Sitagliptin Phosphate | 71 | suppressed |
| Finasteride | Finasteride | 69 | 14 |
| Prednisone | Prednisone | 68 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | suppressed |
| Carvedilol | Carvedilol | 66 | 13 |
| Atenolol | Atenolol | 64 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 62 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 12 |
| Glipizide | Glipizide | 53 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 19 |
| Alendronate Sodium | Alendronate Sodium | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 18 |
| Montelukast Sodium | Montelukast Sodium | 48 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Clonazepam | Clonazepam | 45 | 11 |
| Tramadol Hcl | Tramadol Hcl | 45 | 11 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Novolin R | Insulin Regular, Human | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Rivastigmine | Rivastigmine | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 26 | 11 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Levofloxacin | Levofloxacin | 25 | 15 |
| Linzess | Linaclotide | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Austedo Xr | Deutetrabenazine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 19 | suppressed |
| Misoprostol | Misoprostol | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.08 · 8 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, ELIQUIS, NURTEC ODT, REXULTI, Zunveyl | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lundbeck LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error